NCT02628106View on ClinicalTrials.gov

Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Diabetic Nephropathy
Interventions
DRUG

Lipo-PGE1

all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days

Trial Locations (1)

641000

Zhichengli, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT02628106 - Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy | Biotech Hunter | Biotech Hunter